Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) EBITDA: 2019-2024

Historic EBITDA for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to -$213.0 million.

  • Nurix Therapeutics' EBITDA fell 67.34% to -$91.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$267.2 million, marking a year-over-year decrease of 37.96%. This contributed to the annual value of -$213.0 million for FY2024, which is 37.38% down from last year.
  • As of FY2024, Nurix Therapeutics' EBITDA stood at -$213.0 million, which was down 37.38% from -$155.1 million recorded in FY2023.
  • Nurix Therapeutics' EBITDA's 5-year high stood at -$65.0 million during FY2020, with a 5-year trough of -$213.0 million in FY2024.
  • In the last 3 years, Nurix Therapeutics' EBITDA had a median value of -$183.9 million in 2022 and averaged -$184.0 million.
  • Per our database at Business Quant, Nurix Therapeutics' EBITDA crashed by 192.24% in 2020 and then increased by 15.67% in 2023.
  • Over the past 5 years, Nurix Therapeutics' EBITDA (Yearly) stood at -$65.0 million in 2020, then crashed by 81.41% to -$117.9 million in 2021, then slumped by 55.97% to -$183.9 million in 2022, then increased by 15.67% to -$155.1 million in 2023, then slumped by 37.38% to -$213.0 million in 2024.